MSTR has shed another 15% this week to close at $103.84 — breaking decisively below the $122 level cited in last week's note — and the short position that was already anchored at 15% of the float has barely moved, confirming that bears are not treating this as a buying opportunity.
The positioning picture tells a story of patient, well-funded shorts. Short interest nudged fractionally lower on the week — down less than 1% to roughly 40.8 million shares, still 15.2% of the free float — a figure that has now been range-bound between 39 and 41 million shares for seven consecutive weeks. Shorts are not covering into the slide. The reason is clear in the borrow economics: cost to borrow ticked up slightly to 0.50% but remains negligible, making patience essentially free. Availability has actually loosened this week, recovering to 201% from 174% on Monday, meaning roughly two shares remain available to lend for every one already lent. That is squarely in the normal range. There is no mechanical squeeze pressure building here. The ORTEX short score has crept back up to 60.8, close to the week's high of 62.0 reached on Monday, consistent with a moderately elevated short conviction reading rather than an extreme. Options, by contrast, have turned incrementally less defensive: the put/call ratio eased to 0.97, about 1.6 standard deviations below its 20-day average of 1.04. That's the opposite direction from the stock's move — call buyers stepped in as the stock fell, suggesting at least some participants are fading the decline rather than hedging into it further.
The Street remains nominally bullish, but the price target math is looking stretched. The consensus is Buy, with the mean target at $351 — implying roughly 240% upside from current levels. The data-consistency caveat is real here: with the stock at $103, the $570 target from Benchmark and $400 from TD Cowen reflect views formed when MSTR was trading at levels roughly double current prices. The most recent action, from Canaccord Genuity on June 3, cut the target from $224 to $163 — itself now well above the stock. Mizuho trimmed from $320 to $265 in late May. The direction of travel in recent analyst moves is downward, even if ratings remain positive. Bulls point to the bitcoin-per-share accumulation thesis, the STRC digital credit structure, and the optionality embedded in a leveraged BTC proxy. Bears argue that recent BTC price weakness has produced significant non-GAAP losses, EPS momentum ranks in the 6th percentile over 30 days and 8th percentile over 90 days, and the EV/EBITDA multiple at 859x leaves essentially no margin for error. The ORTEX stock score has slid from 53 to 50 over the past month, driven almost entirely by deteriorating momentum.
Institutional ownership offers one point of genuine interest. Capital Research and Management added over 12.8 million shares in the most recent filing period, taking its stake to 12.3% — a meaningful conviction add into what has been a difficult stretch for the stock. BlackRock added 3.1 million shares to reach 5%. Those are not exits. On the other side, insiders have been selling: the CEO, CFO, and chief accounting officer all sold on June 9, and a director sold again on June 17. The insider net 90-day figure is a small positive ($11.8 million net), but the recent cluster of C-suite sales just above current prices is the kind of detail worth noting in isolation.
Close peers diverged sharply this week. MARA gained 5.5% and BTBT surged 28%, while MSTR fell 15% — suggesting the weakness is not purely a BTC-proxy sector story but something more specific to the Strategy equity structure or its premium to net asset value compressing. The next scheduled earnings release is August 5. Between now and then, the key questions are whether BTC stabilises enough to arrest the premium compression, whether further analyst target reductions close the gap to the stock, and whether the availability of cheap borrow continues to give shorts the luxury of holding through any short-term volatility.
See the live data behind this article on ORTEX.
Open MSTR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
